Akebia Therapeutics Inc AKBA:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 9:25 AM EDT
2.49quote price arrow up+0.02 (+0.81%)
Volume
18,431
Close
2.47UNCH (UNCH)
52 week range
2.09 - 12.48

...

Loading . . .
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close2.47
  • 52 Week High12.48
  • 52 Week High Date07/28/20
  • 52 Week Low2.09
  • 52 Week Low Date10/30/20

Key Stats

  • Market Cap395.50M
  • Shares Out160.12M
  • 10 Day Average Volume7.11M
  • Dividend-
  • Dividend Yield-
  • Beta1.66
  • YTD % Change-11.79

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close2.47
  • 52 Week High12.48
  • 52 Week High Date07/28/20
  • 52 Week Low2.09
  • 52 Week Low Date10/30/20
  • Market Cap395.50M
  • Shares Out160.12M
  • 10 Day Average Volume7.11M
  • Dividend-
  • Dividend Yield-
  • Beta1.66
  • YTD % Change-11.79

RATIOS/PROFITABILITY

  • EPS (TTM)-2.75
  • P/E (TTM)-0.90
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-233.237M
  • ROE (MRQ)-128.57%
  • Revenue (MRQ)259.13M
  • Gross Margin (MRQ)38.54%
  • Net Margin (MRQ)-151.39%
  • Debt To Equity (MRQ)45.17%

EVENTS

  • Earnings Date08/09/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Akebia Therapeutics Inc

There is no recent news for this security.

Profile

MORE
Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company's lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD). It is involved in developing vadadustat as an oral therapy. The Company's vadadustat is a HIF-prolyl-hydroxylase (HIF-PH) inhibitor in Phase III development for the...
Adrian Adams
Non-Executive Chairman
John Butler
President
Michel Dahan
Chief Operating Officer
David Spellman
Chief Financial Officer
Address
245 1st St
Cambridge, MA
02142-1200
United States

Top Peers

SYMBOLLASTCHG%CHG
PBYI
Puma Biotechnology Inc
7.76UNCHUNCH
OVID
Ovid Therapeutics Inc
3.71UNCHUNCH
ICPT
Intercept Pharmaceuticals Inc
16.69UNCHUNCH
CLVS
Clovis Oncology Inc
4.76UNCHUNCH
ATNX
Athenex Inc
3.66UNCHUNCH